Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination

Daprodustat, an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease. This phase 1, nonrandomized, 2‐period, crossover study in 6 healthy men characterized the absorption, distribution, and excretion of daprodustat when a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahar, Kelly M., Caltabiano, Stephen, Andrews, Susan, Ramanjineyulu, Bandi, Chen, Liangfu, Young, Graeme, Pereira, Adrian, Lindsay, Alistair C., van den Berg, Frans, Cobitz, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298194/
https://www.ncbi.nlm.nih.gov/pubmed/34713596
http://dx.doi.org/10.1002/cpdd.1029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298194/
https://www.ncbi.nlm.nih.gov/pubmed/34713596
http://dx.doi.org/10.1002/cpdd.1029

Ejemplares similares